Generate Biomedicines Q3 net loss widens 46% to $87.7 million; revenue falls 56% to $4.2 million
GENB•Generate Biomedicines’ third-quarter 2026 net loss widened 46% year over year to $87.7 million, while revenue fell 56% to $4.2 million. It had $404.2 million in cash, cash equivalents and marketable securities at September 30, with projected funding runway into the first half of 2028.
1. Quarterly results
Generate Biomedicines’ third-quarter 2026 net loss widened 46% year over year to $87.7 million, and revenue fell 56% to $4.2 million. Research and development expenses rose 32% to $82.3 million, primarily driven by investment in GB-0895 Phase 3 severe asthma trials.
2. Cash and programs
Cash, cash equivalents and marketable securities totaled $404.2 million at September 30, with projected funding runway into the first half of 2028. The Zealand Pharma collaboration delivered $30 million upfront in October, with nearly $1.2 billion in potential milestones for obesity and metabolic-disease programs. GB-0895 remains in two Phase 3 severe asthma studies evaluating twice-yearly dosing; COPD findings showed sustained pharmacological activity for at least six months.
